Literature DB >> 1708088

Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.

P Huang1, W Plunkett.   

Abstract

The action of 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) on RNA metabolism was evaluated both in whole cells and in cell-free systems. F-ara-A was converted to its 5'-triphosphate, F-ara-ATP, in cells and then incorporated into RNA as well as DNA. F-ara-A inhibited RNA synthesis in cultured cells in a concentration-dependent manner. This inhibition was mediated mainly by F-ara-ATP. Experiments using isolated nuclei demonstrated that RNA polymerases I, II, and III accounted for 24, 73, and 3% of the total RNA synthesis activity, respectively. About 88% of the total inhibition was attributed to the suppression of RNA polymerase II activity. In cultured cells, F-ara-A was preferentially incorporated into the poly(A)+ RNA fraction. Approximately 78% of the incorporated F-ara-A monophosphate residues were located at the terminal position of the RNA chain. The incorporation of F-ara-A monophosphate into mRNA resulted in premature termination of the RNA transcript and impaired its functioning as a template for protein synthesis. The inhibitory action of F-ara-A on RNA metabolism is a unique property of this compound, differing from the action of arabinosylcytosine and arabinosyladenine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708088

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  Dynamic metabolic labeling of DNA in vivo with arabinosyl nucleosides.

Authors:  Anne B Neef; Nathan W Luedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

Review 3.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.

Authors:  B Cervasi; M Paiardini; S Serafini; A Fraternale; M Menotta; J Engram; B Lawson; S I Staprans; G Piedimonte; C F Perno; G Silvestri; M Magnani
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

Review 5.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

6.  Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.

Authors:  Mazin A Moufarij; Deepa Sampath; Michael J Keating; William Plunkett
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

Review 7.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.

Authors:  Lisa S Chen; William Plunkett; Varsha Gandhi
Journal:  Leuk Res       Date:  2008-04-22       Impact factor: 3.156

Review 9.  Potential immunological action of purine nucleoside analogues.

Authors:  G Dighiero
Journal:  Drugs       Date:  1994       Impact factor: 9.546

10.  Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.

Authors:  Shigeki Hirabayashi; Ryuji Uozumi; Tadakazu Kondo; Yasuyuki Arai; Takahito Kawata; Naoyuki Uchida; Atsushi Marumo; Kazuhiro Ikegame; Takahiro Fukuda; Tetsuya Eto; Masatsugu Tanaka; Atsushi Wake; Junya Kanda; Takafumi Kimura; Ken Tabuchi; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada; Shingo Yano
Journal:  Cancer Med       Date:  2021-06-16       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.